Replies to post #164815 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

The number in the Phase III DCVax-L trial provided to the public for PFS at approximately 30 months after median enrollment, (which was 25% people still Progression free on or about January 2016) does not come close to what Dr. Liau stated patients with GBM typically progress at -- 95% in one to two years (aka: only 5% progression free). Dr. Liau had to be talking about statistics for typical SOC when she was quoted in July 2017. By the way, months prior to that, just a couple weeks before Dr. Liau spoke in an earlier presentation in December 2016, I had posted that it would not be inconceivable that nearly all original placebo had progressed. Nearly all. "95%" in "one to two" years post PFS eventing is akin to nearly all.